1. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Issue 11 (November 2022) Authors: Wainberg, Zev A; Enzinger, Peter C; Kang, Yoon-Koo; Qin, Shukui; Yamaguchi, Kensei; Kim, In-Ho; Saeed, Anwaar; Oh, Sang Cheul; Li, Jin; Turk, Haci Mehmet; Teixeira, Alexandra; Borg, Christophe; Hitre, Erika; Udrea, Adrian A; Cardellino, Giovanni Gerardo; Sanchez, Raquel Guardeño; Collins, Helen; ... Journal: Lancet oncology Issue: Volume 23:Issue 11(2022) Page Start: 1430 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Issue 1 (January 2021) Authors: O'Hara, Mark H; O'Reilly, Eileen M; Varadhachary, Gauri; Wolff, Robert A; Wainberg, Zev A; Ko, Andrew H; Fisher, George; Rahma, Osama; Lyman, Jaclyn P; Cabanski, Christopher R; Mick, Rosemarie; Gherardini, Pier Federico; Kitch, Lacey J; Xu, Jingying; Samuel, Theresa; Karakunnel, Joyson; Fairchild... Journal: Lancet oncology Issue: Volume 22:Issue 1(2021) Page Start: 118 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Issue 9 (September 2020) Authors: Subbiah, Vivek; Lassen, Ulrik; Élez, Elena; Italiano, Antoine; Curigliano, Giuseppe; Javle, Milind; de Braud, Filippo; Prager, Gerald W; Greil, Richard; Stein, Alexander; Fasolo, Angelica; Schellens, Jan H M; Wen, Patrick Y; Viele, Kert; Boran, Aislyn D; Gasal, Eduard; Burgess, Paul; Ilankumaran,... Journal: Lancet oncology Issue: Volume 21:Issue 9(2020) Page Start: 1234 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer – Authors' reply. Issue 11 (November 2020) Authors: Subbiah, Vivek; Lassen, Ulrik; Gasal, Eduard; Burgess, Paul; Wainberg, Zev A Journal: Lancet oncology Issue: Volume 21:Issue 11(2020) Page Start: e516 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design. (31st October 2018) Authors: Moehler, Markus; Ryu, Min-Hee; Dvorkin, Mikhail; Lee, Keun-Wook; Coşkun, Hasan Ş; Wong, Rachel; Chung, Hyun C; Poltoratsky, Artem; Tsuji, Akihito; Yen, Chia Jui; Muntean, Alina S; Le Sourd, Samuel; Vaccaro, Gina M; Overton, Lindsay; Boku, Narikazu; Wainberg, Zev A; Patel, Manish; Sharma, Maitreyi... Journal: Future oncology Issue: Volume 15:Number 6(2019) Page Start: 567 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure–safety analyses in patients with metastatic pancreatic cancer. (20th November 2021) Authors: Brendel, Karl; Bekaii‐Saab, Tanios; Boland, Patrick M; Dayyani, Farshid; Dean, Andrew; Macarulla, Teresa; Maxwell, Fiona; Mody, Kabir; Pedret‐Dunn, Anna; Wainberg, Zev A; Zhang, Bin Journal: CPT: pharmacometrics & systems pharmacology Issue: Volume 10:Number 12(2021) Page Start: 1550 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Ramucirumab plus pembrolizumab: can we make the maths work?. Issue 8 (August 2019) Authors: Klempner, Samuel J; Wainberg, Zev A Journal: Lancet oncology Issue: Volume 20:Issue 8(2019) Page Start: 1041 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Issue 3 (March 2019) Authors: Luft, Alexander V.; Karaseva, Nina A.; Kowalyszyn, Rubén Dario; Hernandez, Carlos Alberto; Csoszi, Tibor; De Vita, Ferdinando; Pfeiffer, Per; Sugimoto, Naotoshi; Kocsis, Judit; Csilla, Andràs; Bodoky, Gyorgy; Garnica Jaliffe, Georgina; Protsenko, Svetlana; Madi, Ayman; Wojcik, Elzbieta; Brenner, ... Journal: Lancet oncology Issue: Volume 20:Issue 3(2019) Page Start: 420 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. The importance of optimal drug sequencing in metastatic colorectal cancer: biological rationales for the observed survival benefit conferred by first-line treatment with EGFR inhibitors. (August 2015) Authors: Wainberg, Zev A; Drakaki, Alexandra Journal: Expert opinion on biological therapy Issue: Volume 15:Number 8(2015:Aug.) Page Start: 1205 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗